Literature DB >> 12950388

An efficient method for the rapid establishment of Epstein-Barr virus immortalization of human B lymphocytes.

H-M Oh1, J-M Oh, S-C Choi, S-W Kim, W-C Han, T-H Kim, D-S Park, C-D Jun.   

Abstract

Several methods have been developed for the immortalization of B lymphocytes by Epstein-Barr virus (EBV). We developed an efficient method which reduces the time from culture initiation to immortalization and cryopreservation. Two infections of EBV to lymphocytes, and the use of phorbol ester-induced EBV stock significantly improved immortalization efficiency and reduced the time between initiation and immortalization and cryopreservation. The resulting cell bank was used to produce DNA for genetic studies focusing on the genes involved in immune and autistic disorders.

Entities:  

Mesh:

Year:  2003        PMID: 12950388      PMCID: PMC6495897          DOI: 10.1046/j.1365-2184.2003.00276.x

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  19 in total

1.  Sample age and Epstein-Barr virus transformation of cryopreserved lymphocytes.

Authors:  J A Reidy; V A Wheeler
Journal:  In Vitro Cell Dev Biol       Date:  1992-06

2.  Long-term C-cell-mediated immunity to Epstein-Barr virus in man. II. Components necessary for regression in virus-infected leukocyte cultures.

Authors:  A B Rickinson; D J Moss; J H Pope
Journal:  Int J Cancer       Date:  1979-05-15       Impact factor: 7.396

3.  12-O-tetradecanoylphorbol-13-acetate induces Epstein-Barr virus reactivation via NF-kappaB and AP-1 as regulated by protein kinase C and mitogen-activated protein kinase.

Authors:  X Gao; K Ikuta; M Tajima; T Sairenji
Journal:  Virology       Date:  2001-07-20       Impact factor: 3.616

4.  Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes.

Authors:  D J Moss; A B Rickinson; J H Pope
Journal:  Int J Cancer       Date:  1978-12       Impact factor: 7.396

5.  Establishment of continuous lymphoblast cultures from leukocytes of gibbons (Hylobates lar).

Authors:  J Werner; G Henle; C A Pinto; R F Haff; W Henle
Journal:  Int J Cancer       Date:  1972-11       Impact factor: 7.396

6.  Use of a simple method for the Epstein-Barr virus transformation of lymphocytes from members of large families of Réunion Island.

Authors:  M Ventura; A Gibaud; J Le Pendu; D Hillaire; G Gérard; D Vitrac; R Oriol
Journal:  Hum Hered       Date:  1988       Impact factor: 0.444

7.  An efficient method for routine Epstein-Barr virus immortalization of human B lymphocytes.

Authors:  F E Wall; R D Henkel; M P Stern; H B Jenson; M P Moyer
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-02       Impact factor: 2.416

8.  Epstein-Barr virus-induced transformation of human leukocytes after cell fractionation.

Authors:  U Schneider; H zur Hausen
Journal:  Int J Cancer       Date:  1975-01-15       Impact factor: 7.396

9.  Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle.

Authors:  Lyndle Gradoville; David Kwa; Ayman El-Guindy; George Miller
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

10.  Characteristics of Epstein-Barr virus activation of human B lymphocytes.

Authors:  A G Bird; S Britton; I Ernberg; K Nilsson
Journal:  J Exp Med       Date:  1981-09-01       Impact factor: 14.307

View more
  32 in total

1.  Improved efficiency of EBV transformation of B-lymphocytes.

Authors:  Helen Bass; Christopher Darke
Journal:  Cell Prolif       Date:  2004-12       Impact factor: 6.831

2.  Feasibility of using cryopreserved lymphoblastoid cells to diagnose some lysosomal storage diseases.

Authors:  A S de Mello; F Provin; K Michelin-Tireli; M V Camelier; J C Coelho
Journal:  Cell Prolif       Date:  2010-04       Impact factor: 6.831

3.  High-potentiality preliminary selection criteria and transformation time-dependent factors analysis for establishing Epstein-Barr virus transformed human lymphoblastoid cell lines.

Authors:  I-C Chang; J-Y Wu; H-I Lu; H-W Ko; J-L Kuo; C-Y Wang; P-S Shen; S-M Hwang
Journal:  Cell Prolif       Date:  2006-12       Impact factor: 6.831

4.  Connectivity map analysis of nonsense-mediated decay-positive BMPR2-related hereditary pulmonary arterial hypertension provides insights into disease penetrance.

Authors:  Charles Flynn; Siyuan Zheng; Ling Yan; Lora Hedges; Bethany Womack; Josh Fessel; Joy Cogan; Eric Austin; James Loyd; James West; Zhongming Zhao; Rizwan Hamid
Journal:  Am J Respir Cell Mol Biol       Date:  2012-02-03       Impact factor: 6.914

5.  Induction of Epstein-Barr virus (EBV) lytic cycle in vitro causes oxidative stress in lymphoblastoid B cell lines.

Authors:  Bochra Gargouri; Jos Van Pelt; Abd El Fatteh El Feki; Hammadi Attia; Saloua Lassoued
Journal:  Mol Cell Biochem       Date:  2008-12-11       Impact factor: 3.396

6.  B lymphocytes from patients with a hypomorphic mutation in STAT3 resist Epstein-Barr virus-driven cell proliferation.

Authors:  Siva Koganti; Amanda de la Paz; Alexandra F Freeman; Sumita Bhaduri-McIntosh
Journal:  J Virol       Date:  2013-10-30       Impact factor: 5.103

7.  A Simple Red Blood Cell Lysis Method for the Establishment of B Lymphoblastoid Cell Lines.

Authors:  Xi Liu; Chongfeng Xu; Ziyuan Duan
Journal:  J Vis Exp       Date:  2017-01-14       Impact factor: 1.355

8.  Pharmacologic correction of dominant-negative GH1 deficiency causing mutations.

Authors:  Justin S Poling; John A Phillips; Joy D Cogan; Rizwan Hamid
Journal:  Clin Transl Sci       Date:  2011-06       Impact factor: 4.689

9.  Capacity of robot handling for Epstein-Barr virus transformation.

Authors:  I-C Chang; H-W Ko; S-M Hwang
Journal:  Cell Prolif       Date:  2009-02       Impact factor: 6.831

10.  A molecular basis for variation in clinical severity of isolated growth hormone deficiency type II.

Authors:  Rizwan Hamid; John A Phillips; Cindy Holladay; Joy D Cogan; Eric D Austin; Philippe F Backeljauw; Sharon H Travers; James G Patton
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.